Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia.

Leukemia research - 1 Feb 2010

Hartman A, van Schaik R H N, van der Heiden I P, Broekhuis M J C, Meier M, den Boer M L, Pieters R

Abstract excerpt

INTRODUCTION: Impaired motor performance in children who completed treatment for acute lymphoblastic leukemia (ALL) may be related to polymorphisms of the metabolising gene CYP3A5 or vincristine toxicity related genes MDR-1 and MAPT. METHODS: Motor performance was measured with the Movement Asses...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily B, Member 1
Share to Cytochrome P-450 CYP3A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Pharmacogenetics

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to Psychomotor Performance

Share to tau Proteins

Share to Vincristine

Source

Identifiers

PMID: 19467705
DOI: 10.1016/j.leukres.2009.04.027

Genes

MAPT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19467705-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia.PMID 19467705Read ↗

Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia.Semantic proximity Read ↗

Genetic polymorphisms in candidate genes are not associated with increased vincristine-related peripheral neuropathy in Arab children treated for acute childhood leukemia: a single institution study.Semantic proximity Read ↗

CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer.Semantic proximity Read ↗

Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach.Semantic proximity Read ↗

Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseases.Semantic proximity Read ↗

Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia.Semantic proximity Read ↗

Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia.Semantic proximity Read ↗

The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia.Semantic proximity Read ↗

Assessment of gross motor skills and phenotype profile in children 9-11 years of age in survivors of acute lymphoblastic leukemia.Semantic proximity Read ↗

Developmental pharmacokinetics of etoposide in 67 children: lack of dexamethasone effect.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.